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16The need for treatment of hemodynamic instability
following carotid endarterectomy is associated with
increased perioperative and 1-year morbidity and
mortality
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Gheorghe Doros, PhD,b Philip P. Goodney, MD,c Jack L. Cronenwett, MD,c and Alik Farber, MD,b on
behalf of the Vascular Study Group of New England, Shreveport, La; Boston, Mass; and Lebanon, NH
Objective: The objective of this study was to evaluate the outcomes of patients after carotid endarterectomy (CEA) who
developed postoperative hypertension or hypotension requiring the administration of intravenous vasoactive medication
(IVMED).
Methods:We examined consecutive, primary elective CEA performed by 128 surgeons within the Vascular Study Group of
New England (VSGNE) database (2003-2010) and compared outcomes of patients who required postoperative IVMED
to treat hyper- or hypotension with those who did not. Outcomes included perioperative death, stroke, myocardial
infarction (MI), congestive heart failure (CHF), hospital length of stay, and 1-year stroke or death. Propensity score
matching was performed to facilitate risk-adjusted comparisons. Multivariable regression models were used to compare
the association between IVMED and outcomes in unmatched and matched samples. Factors associated with use of
IVMED in postoperative hypertension and hypotension were evaluated, and predictive performance of multivariable
models was examined using receiver operating characteristic (ROC) curves.
Results:Of 7677 elective CEAs identiﬁed, 23% received IVMED for treatment of either postoperative hypertension (11%)
or hypotension (12%). Preoperative neurological symptomatic status (20%) was similar across cohorts. In the crude
sample, the use of IVMED to treat postoperative hypertension was associated with increased 30-day mortality (0.7% vs
0.1%; P < .001), stroke (1.9% vs 1%; P[ .018), MI (2.4% vs 0.5%; P < .001), and CHF (1.9% vs 0.5%; P < .001). The use
of IVMED to treat postoperative hypotension was also associated with increased perioperative mortality (0.8% vs 0.1%;
P < .001), stroke (3.2% vs 1.0%; P < .001), MI (2.7% vs 0.5%; P < .001), and CHF (1.7% vs 0.5%; P < .001), as well as
1-year death (5.1% vs 2.9%; P < .001) or stroke (4.2% vs 2.1%; P < .001). Hospital length of stay was signiﬁcantly longer
among patients who needed IVMED for postoperative hypertension (2.8 6 4.7 days vs 1.7 6 5.5 days; P < .001) and
hypotension (2.8 6 5.9 days vs 1.7 6 5.5 days; P < .001). In multivariable analysis, IVMED for postoperative hyper-
tension was associated with increased MI, stroke, or death (odds ratio, 2.6; 95% conﬁdence interval [CI], 1.6-4.1; P <
.001). Similarly, IVMED for postoperative hypotension was associated with increased MI, stroke, or death (odds ratio,
3.2; 95% CI, 2.1-5.0; P < .001), as well as increased 1-year stroke or death (hazard ratio, 1.6; 95% CI, 1.2-2.2; P[ .003).
Smoking, coronary artery disease, and clopidogrel (ROC, 0.59) were associated with postoperative hypertension
requiring IVMED, whereas conventional endarterectomy and general anesthesia were associated with postoperative
hypotension requiring IVMED (ROC, 0.58). The unitization of IVMED varied between 11% and 38% across VSGNE,
and center effect did not affect outcomes.
Conclusions: Postoperative hypertension requiring IVMED after CEA is associated with increased perioperative mortality,
stroke, and cardiac complications, whereas signiﬁcant postoperative hypotension is associated with increased perioperative
mortality, cardiac, or stroke complications, as well as increased 1-year death or stroke following CEA. The utilization of
IVMED varied across centers and, as such, further investigation into this practice needs to occur in order to improve
outcomes of these at-risk patients. (J Vasc Surg 2014;59:16-24.)Carotid endarterectomy (CEA) is effective in pre-
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been reported in up to 56%6-8 and hypotension in up to
40% of patients undergoing CEA.10,11
Hemodynamic instability after CEA often requires the
use of intravenous vasoactive medication (IVMED) and
may lead to prolonged intensive care unit and hospital
stay.9,11,12 Hypertension may potentially lead to wound
hematoma, cardiac and cerebral complications, and exacer-
bate the sequelae of cerebral hyperperfusion syndrome.7,8
Hypotension, likewise, may cause decreased myocardial
and cerebral perfusion that may result in myocardial infarc-
tion (MI) and ischemic stroke.13 Despite these concerns,
the short- and long-term clinical effects of postoperative
hemodynamic changes remain uncertain.7,8,10,11,13 Some
authors have reported increased mortality and complication
rates in patients after CEA who developed postoperative
hemodynamic changes,7,8,10,11 while others observed no
differences in outcomes.10,13 Using a large clinical data-
base, we sought to evaluate the clinical course of patients
who developed signiﬁcant postoperative hypertension or
hypotension following CEA.
METHODS
Patients. Using the Vascular Study Group of New
England (VSGNE) database, we evaluated patients who
underwent primary CEA. The VSGNE is a regional coop-
erative quality improvement initiative organized in 2002 to
prospectively study patients treated with vascular interven-
tions aiming to improve regional outcomes in vascular
surgery. The details of this registry have been published
previously,14 and additional information is available at
www.vsgne.org. The Institutional Review Board at Boston
University School of Medicine has approved the use of de-
identiﬁed data for this study.
We queried the database for those patients who experi-
enced postoperative hypertension or hypotension and were
treated with IVMED after primary CEA. The study cohort
included consecutive primary elective CEA performed by
128 surgeons practicing at 30 academic and community
hospitals. Of the 8711 CEAs performed between 2003
and 2010, we excluded nonelective CEA (n ¼ 969), those
missing information for postoperative IVMED (n ¼ 8),
and those who received postoperative IVMED for both
hypertension and hypotension (n ¼ 57).
Outcome and variable deﬁnitions. We reviewed the
demographics, pre-existing medical comorbidities, and
operative details for these patients. More than 100 demo-
graphic and clinical variables were collected prospectively
for each procedure and entered into the VSGNE data-
base.14 Deﬁnitions of medical comorbidities in VSGNE
have been previously published.14 We deﬁned clinically
signiﬁcant postoperative hypertension or hypotension as
the need for the administration of IVMED such as phen-
ylephrine, dopamine, nitroglycerine, or nitroprusside either
intermittently or as a continuous infusion in the post-
operative period following CEA. Patients who received
only intraoperative vasoactive agents were not included.
The exact vasoactive medication used, the dosage, durationof treatment, and exact triggers for administration were not
recorded in the database.
Main outcomes included perioperative death, MI, con-
gestive heart failure (CHF), stroke (combination of ipsila-
teral and contralateral stroke), hospital length of stay (LOS),
and a composite outcomeofMI, stroke, or death. In addition,
we also evaluated 1-year outcomes of survival and stroke. MI
was deﬁned in the database as new electrocardiographic ST
and T wave changes on electrocardiogram, troponin eleva-
tion, or documentation by echocardiogram or other imaging
modality. CHF was deﬁned as new pulmonary edema docu-
mented by chest radiograph and requiring treatment ormoni-
toring in the intensive care unit (www.vsgne.org).
Statistical analysis. Outcomes were compared based
on administration of IVMED to treat either postoperative
hypertension or hypotension after CEA. Baseline character-
istics were compared between patients who received
IVMED for postoperative hypertension with those who
did not receive IVMED for treatment of either postopera-
tive hypertension or hypotension using c2 test for categor-
ical variables and Student t-test for continuous variables.
Similar analyses were performed comparing patients who
received IVMED for postoperative hypotension with those
who did not.
Additional analyses were performed using propensity
score matching to select patients for comparison bet-
ween these groups. The two propensity-matched cohorts
included 621 patients who underwent CEA who received
IVMED for postoperative hypertension with 2484 CEA
patients who did not; and 629 CEA patients who required
IVMED for postoperative hypotension with 2516 CEA
patients who did not. Propensity scores were calculated
based on the following factors that were signiﬁcant in
bivariate analysis in these two different groups of patients;
IVMED for postoperative hypertension: age, smoking,
hypertension, coronary artery disease (CAD), diabetes,
preoperative beta blocker use, and type of procedure
(conventional CEA vs eversion CEA); Use of IVMED
for postoperative hypotension: CAD, chronic obstructive
pulmonary disease (COPD), beta-blocker use, type of
procedure, and type of anesthesia used. These scores
were used to select two pairs of evenly matched groups
using 1 to 4 ratios for comparison.
Separate multivariable analyses were performed for the
crude study sample and the propensity-score-matched
cohorts. Factors identiﬁed in previous VSGNE studies to
be associated with cardiac complications after CEA (age,
smoking, diabetes, CAD, COPD, abnormal stress test,
beta-blocker use, and creatinine >1.8 mg/dL)15 and
stroke or death (age >80, hypertension, ipsilateral carotid
stenosis, contralateral carotid stenosis >70%, symptom
status)16 were incorporated into the multivariable models.
To account for the possible effect of individual practice
pattern on postoperative outcomes, the utilization of
IVMED was compared with c2 test in all centers perform-
ing CEA in VSGNE. Additionally, generalized estimating
equations analyses accounting for possible within-center
correlation of subjects were performed for the main
Table I. Demographic, clinical, and procedural variables of patients treated with intravenous vasoactive medications
(IVMED) for hypertension and hypotension
Characteristic
No medications
(n ¼ 5911)
Hypertension medications
(n ¼ 824) P value
Hypotention medications
(n ¼ 942) P value
Demographics
Age, years 69.6 6 9.2 68.7 6 9.4 .011 69.7 6 9.3 .724
Gender
Male 3529 (59.7) 502 (60.9) .503 530 (56.3) .046
Female 2382 (40.3) 322 (39.1) 412 (43.7)
Race
White 5833 (99.6) 798 (98.2) <.001 934 (99.7) .636
Smoking
Never 1193 (20.2) 146 (17.7) .002 174 (18.5) .474
Prior 2976 (50.4) 386 (46.8) 481 (51.2)
Current 1736 (29.4) 292 (35.4) 285 (30.3)
Medical history
Hypertension 5211 (88.2) 713 (86.6) .204 837 (88.9) .546
CAD 1886 (31.9) 315 (38.2) <.001 329 (34.9) .067
CHF 447 (7.6) 76 (9.2) .095 81 (8.6) .268
COPD 1311 (22.2) 193 (23.4) .423 238 (25.3) .036
Diabetes 1822 (30.8) 282 (34.2) .049 300 (31.8) .530
ASA 5168 (87.4) 716 (87) .718 812 (86.3) .324
Clopidogrel 943 (16) 165 (20) .003 142 (15.1) .498
Beta-blockers
Chronic >30 days 3414 (57.8) 450 (54.6) .199 561 (59.6) .076
One to 30 days 1259 (21.3) 194 (23.5) 213 (22.6)
None 1237 (20.9) 180 (21.8) 167 (17.7)
Symptomatic 1181 (20) 171 (20.8) .607 199 (21.1) .418
Procedure
Type of surgery
Conventional 5306 (89.8) 773 (93.8) <.001 799 (84.9) <.001
Eversion 604 (10.2) 51 (6.2) 142 (15.1)
Anesthesia
Local/regional 712 (12) 102 (12.4) .783 74 (7.9) <.001
General 5199 (88) 722 (87.6) 868 (92.1)
Shunt 2681 (45.4) 395 (48) .154 418 (44.4) .574
Patch 5121 (86.6) 741 (90) .006 764 (81.1) <.001
ASA, Aspirin; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
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of MI, stroke, or death in the crude CEA sample.
Multivariable logistic regression models were used to
examine the risk factors associated with the need of treat-
ment with IVMED for postoperative hypertension or hypo-
tension. Factors that were thought to be clinically associated
with use of the medications and those found to be signiﬁ-
cant in bivariable analysis with P < .2 were entered into
the initial prediction models. Then, using the backward
elimination procedure with alpha level to remain in the
model at .5, the more parsimonious models were con-
structed. The predictive performance of the models was
examined using area under receiver operating characteristic
(ROC) curves. Analysis was performed using SAS 9.2 soft-
ware (SAS Institute, Cary, NC).
RESULTS
Characteristics of the crude cohort. The study
cohort included 7677 consecutive primary elective CEA
in 7096 patients. IVMED were required in 11% (824) of
CEA to treat postoperative hypertension and in 12%
(942) of CEA to treat postoperative hypotension. Seventyseven percent (5911) of CEAs were not associated with the
administration of IVMED to treat either hypertension or
hypotension. Demographic characteristics and preoperative
medications of the crude cohort are listed in Table I.
Overall, 20% of patients were treated for symptomatic
carotid artery stenosis, 89% underwent conventional CEA,
and 89% of procedures were performed under general
anesthesia. Intraoperative carotid shunt and patch were
used in 45% and 86% of procedures, respectively.
Compared with normotensive patients, those with
postoperative hypertension requiring IVMED were
younger, had a higher rate of history of CAD and diabetes,
and were more likely to be treated with clopidogrel. In
addition, they were more likely to undergo conventional
endarterectomy and have a patch placed. There were no
differences with respect to a history of hypertension,
CHF, beta-blocker treatment, indication of surgery, and
type of anesthesia (Table I).
Patients who received IVMED for postoperative hypo-
tension, in comparison with normotensive patients, were
more likely to have a history of COPD, undergo conven-
tional endarterectomy, and have general anesthesia. Age,
Table II. Postoperative and 1-year outcomes of patients treated with intravenous vasoactive medications (IVMED) for
hypertension and hypotension
Characteristic
No medications
(n ¼ 5911)
Hypertension medications
(n ¼ 824) P value
Hypotension medications
(n ¼ 942) P value
Postoperative outcomes
Hospital mortality 5 (0.1) 6 (0.7) <.001 8 (0.8) <.001
MI 32 (0.5) 20 (2.4) <.001 25 (2.7) <.001
CHF 30 (0.5) 16 (1.9) <.001 16 (1.7) <.001
Ipsilateral stroke 42 (0.7) 12 (1.5) .025 24 (2.5) <.001
Contralateral stroke 20 (0.3) 4 (0.5) .507 7 (0.7) .066
Stroke 60 (1) 16 (1.9) .018 30 (3.2) <.001
MI/stroke/death 92 (1.6) 36 (4.4) <.001 52 (5.5) <.001
Hospital LOS, days 1.7 6 5.5 2.8 6 4.7 <.001 2.8 6 5.9 <.001
One-year outcomes
Death 173 (2.9) 29 (3.5) .350 48 (5.1) <.001
Stroke 123 (2.1) 23 (2.8) .190 40 (4.2) <.001
Stroke or death 291 (4.9) 49 (5.9) .209 82 (8.7) <.001
CHF, Congestive heart failure; LOS, length of stay; MI, myocardial infarction; SD, standard deviation.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
Fig 1. Multivariable analysis of the effect of clinically signiﬁcant
post-carotid endarterectomy (CEA) hypertension and hypoten-
sion on perioperative outcomes (crude sample). MI, Myocardial
infarction.
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and neurological symptomatic status were similar between
groups (Table I).
Outcomes of patients requiring IV medication for
postoperative hypertension. Bivariable analysis found
that patients with postoperative hypertension requiring
IVMED had higher in-hospital mortality compared with
those without hemodynamic instability (0.7% vs 0.1%; P <
.001). Rates of perioperative MI and CHF were higher in
those with postoperative hypertension requiring IVMED
(2.4% vs 0.5%; P < .001, and 1.9% vs 0.5%; P < .001,
respectively). Ipsilateral stroke (1.5% vs 0.7%; P ¼ .025)
and overall stroke rates (1.9% vs 1.0%; P ¼ .018) were also
higher in these patients. Finally, patients who required
IVMED for postoperative hypertension had longer total
hospital LOS than those without hemodynamic instability
(2.8 6 4.7 days vs 1.7 6 5.5 days; P < .001). There were
no differences in 1-year mortality (3.5% vs 2.9%; P ¼ .35)
or stroke rates (2.8% vs 2.1%; P ¼ .19; Table II).
On multivariable analysis, signiﬁcant postoperative
hypertension requiring IVMED following CEA was inde-
pendently associated with increased risk of postoperative
MI (odds ratio [OR], 3.8; 95% conﬁdence interval [CI],
2.0-7.5; P < .001), stroke (OR, 1.9; 95% CI, 1.0-3.6;
P ¼ .054), and higher composite MI, stroke, and death
rate (OR, 2.6; 95% CI, 1.6-4.1; P < .001). One-year
outcomes were however not signiﬁcantly different for these
patients (Figs 1 and 2). Hospital LOS was signiﬁcantly
longer in patients who suffered postoperative hypertension
requiring IVMED (means ratio, 1.7; 95% CI, 1.6-1.8; P <
.0001).
Propensity score matching was used as a secondary
risk-adjusted comparison between cohorts of patients
treated with IVMED for postoperative hypertension and
those without hemodynamic instability. Signiﬁcant differ-
ences noted on bivariable analyses including age, smoking
status, CAD, diabetes, type of procedure, and anesthesiatype were successfully adjusted (Supplementary Table I,
online only). Perioperative mortality, MI, CHF, stroke,
and hospital LOS remained signiﬁcantly higher on bivari-
able analyses for patients who required IVMED for signif-
icant postoperative hypertension (Supplementary Table II,
online only). Multivariable analyses of the propensity-
matched cohorts conﬁrmed an independent association
between signiﬁcant postoperative hypertension requiring
IVMED and perioperative MI, stroke, the composite end
point of MI, stroke, or death (Fig 3), and LOS (means
ratio, 1.7; 95% CI, 1.6-1.8; Fig 4).
Outcomes of patients requiring IV medication for
postoperative hypotension. Patients with postoperative
hypotension requiring IVMED had higher hospital
mortality compared with those without hemodynamic
Fig 2. Multivariable analysis of the effect of clinically signiﬁcant
post-carotid endarterectomy (CEA) hypertension and hypotension
on 1-year outcomes (crude sample).
Fig 3. Multivariable analysis of the effect of clinically signiﬁcant
post-carotid endarterectomy (CEA) hypertension and hypoten-
sion on perioperative outcomes (propensity-matched sample). MI,
Myocardial infarction.
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(2.7% vs 0.5%; P < .001) and CHF rates (1.7% vs 0.5%;
P < .001) were signiﬁcantly higher in the hypotension
cohort. Ipsilateral stroke (2.5% vs 0.7%; P < .001) and
overall stroke rates (3.2% vs 1.0%; P < .001) were also
higher in these patients. Hospital LOS was signiﬁcantly
longer in those with IVMED used to treat postoperative
hypotension (2.8 6 5.9 days vs 1.7 6 5.5 days; P <
.001). Lastly, patients with postoperative hypotension
requiring IVMED had higher mortality (5.1% vs 2.9%;
P < .001) and stroke (4.2% vs 2.1%; P < .001) rates at
1-year follow-up (Table II).
On multivariable analysis, clinically signiﬁcant postop-
erative hypotension treated with IVMED was indepen-
dently associated with increased risk of postoperative MI
(OR, 4.3; 95% CI, 2.3-8.2; P < .001), stroke (OR, 2.8;
95% CI, 1.6-4.9; P < .001), and higher composite MI,
stroke, or death rate (OR, 3.2; 95% CI, 2.1-5.0; P <
.001; Fig 1). Hospital LOS was signiﬁcantly longer in
patients who suffered postoperative hypotension (means
ratio, 1.7; 95% CI, 1.6-1.8; P < .0001) requiring IVMED.
Signiﬁcant postoperative hypotension requiring IVMED
was also independently associated with death (OR, 2.0;
95% CI, 1.3-2.9; P < .001), stroke (OR, 1.6; 95% CI,
1.0-2.6; P ¼ .052), and stroke or death (OR, 1.6; 95%
CI, 1.2-2.2; P ¼ .003) at 1 year (Fig 2).
Similarly signiﬁcant differences noted on bivariable
analyses were successfully adjusted in propensity-matched
postoperative hypotension (Supplementary Table I, online
only) analyses. Perioperative mortality, MI, CHF, stroke,
and hospital LOS were signiﬁcantly higher on bivariable
analyses for patients who required IVMED for signiﬁcant
postoperative hypotension (Supplementary Table II, online
only). Multivariable analyses of the propensity-matched
cohorts conﬁrmed an independent association between
signiﬁcant postoperative hypotension requiring IVMED
with perioperative MI, stroke, the composite end point of
MI, stroke, or death (Fig 3), and LOS (means ratio, 1.7;95% CI, 1.6-1.8) as well as an increased 1-year mortality
and stroke (Fig 4).
Factors associated with postoperative hypertension
or hypotension requiring IVMED. The following factors
were associated with postoperative clinically signiﬁcant
hypertension requiring IVMED; current smoking (OR,
1.3; 95% CI, 1.0-1.7; P ¼ .035), history of CAD (OR,
1.3; 95% CI, 1.0-1.5; P ¼ .022), and clopidogrel (OR,
1.4; 95% CI, 1.1-1.7; P ¼ .006). Eversion endarterectomy
(OR, 0.7; 95% CI, 0.5-0.9; P ¼ .007) and use of local or
regional anesthesia (OR, 0.5; 95% CI, 0.4-0.8; P < .001)
were inversely associated with postoperative clinically
signiﬁcant hypotension requiring IVMED. The area
under the ROC curve for the model of factors associated
with signiﬁcant postoperative hypertension was 0.59
(Supplementary Fig, online only). The area under the
ROC curve was 0.58 for the model of factors associated
with signiﬁcant postoperative hypotension (Supplementary
Fig, online only).
Center variation in the use of IVMED. We exam-
ined center variation in the rate of IVMED utilization for
treatment of postoperative hypertension or hypotension
and noted that the practice pattern varied among centers
in New England (P < .001; Fig 5). The overall rate of
IVMED use for either postoperative hypertension or
hypotension following CEA ranged from 11% to 38%.
When center effect was considered in multivariable anal-
yses, the independent association of signiﬁcant post-
operative hypertension or hypotension requiring IVMED
on perioperative MI, stroke, and composite MI, stroke, or
death remained signiﬁcant (data not shown).
DISCUSSION
Postoperative hypertension and hypotension are well-
recognized phenomena after CEA. In this study, up to
27% of CEA patients experienced signiﬁcant postoperative
hypertension or hypotension requiring treatment with
Fig 4. Multivariable analysis of the effect of clinically signiﬁcant
post-carotid endarterectomy (CEA) hypertension and hypotension
on 1-year outcomes (propensity-matched sample).
Fig 5. Utilization of intravenous vasoactive medications (IVMED)
for hypertension or hypotension in centers performing more than
100 carotid endarterectomies (CEAs) per year.
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hypertension were younger and more likely to have CAD
or diabetes. They had a higher perioperative morbidity
and mortality. There was no correlation between postoper-
ative clinically signiﬁcant hypertension requiring IVMED
and 1-year outcomes. Patients who required treatment
for postoperative hypotension were more likely to have
COPD, undergo conventional endarterectomy, and receive
general anesthesia. They suffered increased perioperative
morbidity and mortality as well as increased 1-year mor-
tality and stroke rates. Patients with postoperative clinically
signiﬁcant hemodynamic changes requiring treatment with
IVMED had signiﬁcantly longer hospital LOS.
Signiﬁcant postoperative hypertension was reported in
9% to 56% of patients after CEA.6-8,10,17 The criteria
used to deﬁne signiﬁcant postoperative hypertension within
these studies varied. Due to the limitation of our dataset,
we were not able to determine the exact blood pressure
criteria for initiation or discontinuation of vasoactive treat-
ment in our patients. Rather, we classiﬁed patients with
clinically signiﬁcant postoperative hypertension as those
who required any treatment with IVMED. Given this deﬁ-
nition, our rate of postoperative hypertension requiring
IVMED was 11%, which is similar to the rate observed
by Wong et al (9%) who deﬁned systolic blood pressure
greater than 220 mm Hg as signiﬁcant hypertension.10
Multivariable analysis was used in this study to mini-
mize the effects of potential confounders on postoperative
outcomes. To improve the accuracy of the model, factors
that were previously found to be signiﬁcant for develop-
ment of cardiac complications, stroke, or death using the
VSGNE dataset were incorporated into the analysis.15,16
Further risk-adjusted evaluation was performed using
propensity score matching to select patients for compar-
ison. Both analyses noted an increased perioperative
complication rate in patients with clinically signiﬁcantpostoperative hypertension requiring IVMED treatment.
Other studies have also noted higher complication rates,
including postoperative neurological deterioration7,18,19
and stroke or death8,10 in patients with postoperative
hypertension after CEA. In addition to neurological
complications and death, Wong et al noted a nonsigniﬁcant
statistical association between postoperative hypertension
and MI in their study. In contrast, we found that signiﬁcant
hypertension requiring treatment was associated with an up
to a threefold increase in the rate of postoperative MI. We
believe that ours is the ﬁrst study to describe increased
cardiac complications in patients with clinically signiﬁcant
hypertension after CEA. Although it is not clear whether
signiﬁcant hypertension is a marker or cause of increased
perioperative complications following CEA, it appears
that this phenomenon does not affect 1-year survival or
neurological outcomes.
While postoperative hypotension has been reported in
12% to 40% of CEA,10,11,13 its signiﬁcance remains
unclear.10,13 Some studies have reported increased
mortality and MI11 among such patients, while others
have claimed postoperative hypotension after CEA to be
a transient and benign condition.13 In our study, we deﬁned
clinically signiﬁcant hypotension as the use of IVMED to
treat postoperative hypotension. We found that 16% of
our CEA cohort had clinically signiﬁcant postoperative
hypotension by this deﬁnition, within the range of other re-
ported studies where blood pressure was measured.10,11,13
These patients suffered worse perioperative outcomes
including increased risk of MI, stroke, and death. One-
year survival was decreased, and 1-year stroke rate was
increased. Park et al also reported increased perioperative
mortality, MI, and hospital LOS with clinically signiﬁcant
hypotension11 using criteria of>40 mmHg drop in systolic
blood pressure or a systolic blood pressure<90mmHg sus-
tained for longer than 1 hour after carotid intervention. We
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signiﬁcant postoperative hypertension and hypotension.
There are multiple proposed mechanisms for blood
pressure ﬂuctuation after CEA. Hypertension or hy-
potension can occur as a consequence of baroreceptor
dysfunction.6,20,21 Hypertension can occur secondary to
iatrogenic denervation,20 diminished baroreﬂex activity,22
or decreased carotid sinus sensitivity.23 Other proposed
mechanisms of postoperative hypertension invoke increased
production of cerebral renin24,25 or catecholamines.25,26
Sustained hypotension can occur when distortion of barore-
ceptors in the carotid bulb causes a decrease in sympathetic
activity with subsequent peripheral vasodilatation.27
Previous studies have identiﬁed certain factors to be
associated with signiﬁcant hemodynamic ﬂuctuation after
CEA. Wong et al demonstrated preoperative hypertension,
renal insufﬁciency, neurological instability, and cardiac
dysrhythmia to be associated with postoperative hyperten-
sion.10 Variables including age more than 65 years old,
black race, and intraoperative shunts were also found to
be associated with postoperative hypertension following
CEA.8,28 Predictors of clinically signiﬁcant hypotension
after carotid intervention included preoperative nitrate
use and smoking.11 In our study, factors associated with
clinically signiﬁcant postoperative hypertension requiring
IVMED were history of CAD, smoking, and clopidogrel.
No association between preoperative hypertension and
postoperative hypertension requiring IVMED was found
in this study. We also noted association of clopidogrel
with postoperative hypertension requiring treatment. The
reason for this is unclear; however, a possible explanation
is that a higher number of patients with CAD were treated
with clopidogrel. Factors identiﬁed to be associated with
clinically signiﬁcant postoperative hypotension requiring
IVMED were conventional endarterectomy and general
anesthesia. Similar to other studies,29,30 we had noted
that local regional anesthesia during CEA is less likely to
cause postoperative hypotension requiring treatment. The
accuracy for these predictive models was fairly poor,
judging by area under the ROC curve of less than 0.6.
This is an important observation. Our data suggests that
preoperative clinical factors are not helpful in predicting
which patients are at risk, and therefore, all patients should
be closely monitored during the perioperative period
following CEA.
A number of operative techniques were suggested to
minimize extreme blood pressure ﬂuctuations after CEA
including nerve-sparing dissection31 and carotid sinus
nerve blockage with local anesthesia.17 Due to the limita-
tion of the VSGNE database, we were not able to assess
whether these techniques were used in our patients. A
few studies have suggested that eversion endarterectomy
increases the risk of post-CEA hypertension.32-34 In our
study, eversion endarterectomy was not a factor associated
with clinically signiﬁcant postoperative hypertension
requiring IVMED but was associated with a decreased
need for treatment for postoperative hypotension when
compared with conventional endarterectomy. It is possiblethat denervation of the carotid bulb during eversion
endartectomy may contribute to this ﬁnding.35
The threshold for treatment for postoperative blood
pressure was variable among the institutions and surgeons
participating in the VSGNE, and this likely reﬂects the
true practice patterns in the different centers outside
VSGNE. The description of what is considered to be signif-
icant hyper- or hypotension after CEA in the literature is
also variable,7,8,10,11,13,18,19 and general consensus is lack-
ing. Although we did not ﬁnd any association of center
effect on IVMED utilization and outcomes of these
patients, steps can be taken to address these practice varia-
tions, which might lead to improvement in the outcomes
of these at-risk patients following CEA.
There are a number of important limitations to our
study. First, ours is an observational study of a prospectively
collected database and is not a randomized controlled trial.
Although we attempted to adjust for differences between
patients using multivariable analysis of the crude study
sample and propensity score matching for risk-adjusted
comparisons, there may still be potential confounders that
were not accounted for. Second, we did not have informa-
tion regarding the exact type of IVMED used, the dosage,
or timing of infusion. Due to limitation of the dataset, we
could not determine the exact method of blood pressure
measurement and whether invasive methods were used
during each procedure. Another important shortcoming
was our inability to determine the speciﬁc blood pressure
criteria used for initiating and terminating these vasoactive
medications. Finally, we cannot determine whether the
use of IVMED after CEA caused or resulted from the
increased adverse outcomes reported, such as MI, because
we do not know the timing of the IVMED with respect
to these outcomes.
Despite these limitations, the utility of the VSGNE
database has been validated through other studies,16,36,37
and its strength lies in its comprehensive repository of
speciﬁc variables collected and its regular adjudication
process. Using this prospectively maintained database, we
were able to evaluate a large cohort of CEA patients and
study potential associations of signiﬁcant hemodynamic
changes needing treatment with perioperative and 1-year
outcomes.CONCLUSIONS
Postoperative hypertension and hypotension requiring
IVMED are associated with an increased perioperative
mortality rate, as well as increased rates of stroke or
cardiac complications following CEA. In addition, post-
operative hypotension is associated with increased 1-year
stroke or death rates. Signiﬁcant postoperative hemody-
namic changes after CEA are also associated with longer
hospital LOS. Factors that reliably predict development
of signiﬁcant post-CEA hemodynamic instability were
not identiﬁed. Although this study is hypothesis-
generating, it indicates that the need for IVMED after
CEA is not benign, and that such patients deserve
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at www.jvascsurg.org.DISCUSSIONDr John F. Eidt (Little Rock, Ark). Hemodynamic instability
following carotid endarterectomy has been a topic of considerable
debate for as long as I can remember. We have argued the merits
of local vs regional anesthesia, eversion vs conventional endarterec-
tomy, preservation vs ablation of the carotid sinus nerves, and strict
blood pressure control vs watchful waiting. Vascular surgeons tend
to have very strong opinions regarding the appropriate manage-
ment of periprocedural blood pressure, often based on anecdote
and personal tragedy. Using the VSGNE database, the authors
have attempted to shed some light on this question.
From a population of nearly 7000 carotid endarterectomies
(80% of which were for asymptomatic disease), more than 25%
of patients were treated with vasoactive medications in the postop-
erative period for either hyper- or hypotension. In brief, it appears
that patients who are treated pharmacologically for blood pressure
instability in the postoperative period have higher rates of adverse
cardiovascular outcomes including stoke, death, and MI, and in
the case of hypotension, increased 1-year mortality. Eversion
endarterectomy and the use of locoregional anesthesia were associ-
ated with reduced risk of postoperative hypotension.
The VSGNE has provided us with the answer to a number of
important clinical questions. Unfortunately, I fear that the present
study is constrained by the limitations of the database. On the
postoperative data entry form, there are two check boxes: one
for treatment of hypertension, and the other for hypotension.
Unfortunately, the database does not provide detailed information
regarding the severity of hemodynamic instability including the
absolute blood pressure or its variability. Nor does it provide
detailed information regarding the speciﬁc pharmacological inter-
ventions. In fact, due to the absence of hemodynamic data, it is
unknown whether patients in the control group had similar hemo-
dynamic instability or were simply not treated.
I have three questions:
1. Can you determine if the likelihood of pharmacological treat-
ment of perioperative blood pressure instability is surgeon
speciﬁc? Are some surgeons simply more likely to treat blood
pressure problems than others?
2. Can you differentiate patients who were treated because of
symptoms such as altered mental status, chest pain, or arrhyth-
mias vs those who were completely asymptomatic? Can you
determine from your data the incidence of complications that
might be attributed to the administration of vasoactive agents?
Is it the lowblood pressure that is associatedwith adverse cardio-
vascular events or the treatment of the low blood pressure?
3. What should we do with these data? Can these data be used to
better select anesthetic or surgical technique or perioperative
management strategy?I have one ﬁnal editorial comment: The data available in the
VSGNE are insufﬁciently granular to deﬁnitively answer this
question. Clearly, future studies with additional data will be
required. Unfortunately, I fear that the burden of more data
entry will fall on the surgeon e either in time or in dollars for
additional personnel. We have all become overwhelmed with
completing computerized checkboxes with each new request
for data preceded by the apology that “it only takes a couple
of minutes.” At some point, we need to see a convergence of
data sources across hospital information technologies that will
ﬁnally improve our ability to care for patients rather than
turning us increasingly into data entry technicians. Just as the
black box passively records events on the ﬂight deck, I believe
that we should push for better IT support so that data are
downloaded directly into relevant databases without disrupting
the pilot and crew. Thank you for the privilege of discussing
this paper.
Dr Tze-Woei Tan. Thank you for the comment. For question
one, whether there was any surgeon or center bias, when we look
at utilization of IV MED in high-volume centers and the surgeons
in VSGNE, there was no obvious outlier that use does or does not
use this medication.
For question two, whether the medication was started due to
onset of new symptoms or whether they are started just to treat
a number, due to the limitation of data set, we do not have that
answer.
For question number three, whether the use of this medica-
tion causes complications or rather for example when the patient
had new neurological symptoms after the surgery and medical
was started to treat those new ﬁndings, again, we were not able
to address that using this dataset.
Lastly, what can we do with this ﬁnding? I think when we
decided to go ahead and analyze these data, and we had the similar
issues of not being able to address the exact criteria, the trigger, the
type of medication use, the length of infusion using this dataset, we
proceeded because we can analyze large numbers of patients and
mixed populations of patients treated in tertiary and community
centers, who developed these hemodynamic changes after CEA.
We think the data might reﬂect a real practice pattern. What do
we do with the data? We try to identify these at-risk patients after
CEA. From our data, we know that patients who had signiﬁcant
hypertension are different than those who had signiﬁcant hypoten-
sion based on outcome and characteristics. Although we could not
reliably identify patients judging on AUC value on our predictive
model, we should try to optimize perioperative management of
these at-risk patients who develop signiﬁcant blood pressure
changes after CEA.
Supplementary Fig (online only). Receiver operating curve (ROC) for model predicting need of intravenous
vasoactive medications (IVMED) for hypertension (HTN) or hypotension (HPTN). AUC, Area under the curve.
Supplementary Table I (online only). Demographic, clinical, and procedural variables of propensity-matched cohort of
patients treated with intravenous vasoactive medications (IVMED) for hypertension and hypotension
Characteristic
No medications
(n ¼ 2484)
Hypertension meds
(n ¼ 621) P value
No medications
(n ¼ 2516)
Hypotension medications
(n ¼ 629) P value
Demographics
Age, years 69.2 6 9.4 69 6 9.5 .735 69.4 6 9.3 70 6 9.3 .137
Gender
Male 1502 (60.5) 376 (60.5) .971 1486 (59.1) 355 (56.4) .232
Race
White 2447 (99.6) 599 (97.9) <.001 2479 (99.5) 625 (99.8) .226
Smoking
Never 482 (19.4) 116 (18.7) .915 487 (19.4) 114 (18.2) .290
Prior 1149 (46.3) 291 (46.9) 1302 (51.8) 313 (49.8)
Current 853 (34.3) 214 (34.5) 725 (28.8) 201 (32)
Medical history
Hypertension 2168 (87.3) 543 (87.4) .914 2225 (88.4) 557 (88.6) .933
CAD 905 (36.4) 219 (35.3) .588 758 (30.1) 202 (32.1) .333
CHF 197 (7.9) 64 (10.3) .056 201 (8) 49 (7.8) .869
COPD 607 (24.4) 145 (23.3) .568 581 (23.1) 165 (26.2) .098
Diabetes 877 (35.3) 214 (34.5) .693 790 (31.4) 196 (31.2) .903
ASA 2193 (88.3) 550 (88.7) .768 2211 (87.9) 563 (89.6) .226
Clopidogrel 440 (17.7) 135 (21.7) .021 417 (16.6) 99 (15.7) .610
Beta-blockers
Chronic >30 days 1400 (56.4) 345 (55.6) .760 1513 (60.1) 368 (58.5) .705
One to 30 days 546 (22) 145 (23.3) 528 (21) 134 (21.3)
None 538 (21.7) 131 (21.1) 475 (18.9) 127 (20.2)
Symptomatic 481 (19.4) 130 (20.9) .381 504 (20) 126 (20) .996
Procedure
Type of surgery
Conventional 2308 (92.9) 575 (92.6) .781 2233 (88.8) 557 (88.6) .888
Eversion 176 (7.1) 46 (7.4) 283 (11.2) 72 (11.4)
Anesthesia
Local/regional 319 (12.8) 64 (10.3) .086 185 (7.4) 52 (8.3) .437
General 2165 (87.2) 557 (89.7) 2331 (92.6) 577 (91.7)
Shunt 1172 (47.2) 320 (51.6) .048 1205 (47.9) 291 (46.3) .464
Patch 2272 (91.5) 560 (90.3) .368 2212 (87.9) 553 (87.9) .999
ASA, Aspirin; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; SD, standard deviation.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
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Supplementary Table II (online only). Postoperative and 1-year outcomes of propensity-matched patients treated with
intravenous vasoactive medications (IVMED) for hypertension and hypotension
Characteristic
No medications
(n ¼ 2484)
Hypertension medications
(n ¼ 621) P value
No medications
(n ¼ 2516)
Hypotension medications
(n ¼ 629) P value
Postoperative outcomes
Hospital mortality 1 (0) 5 (0.8) <.001 3 (0.1) 7 (1.1) <.001
MI 15 (0.6) 15 (2.4) <.001 19 (0.8) 17 (2.7) <.001
CHF 11 (0.4) 14 (2.3) <.001 10 (0.4) 10 (1.6) .001
Ipsilateral stroke 19 (0.8) 10 (1.6) .050 21 (0.8) 16 (2.5) <.001
Contralateral stroke 9 (0.4) 4 (0.6) .331 12 (0.5) 5 (0.8) .331
Stroke 28 (1.1) 14 (2.3) .030 33 (1.3) 21 (3.3) <.001
MI/stroke/death 42 (1.7) 28 (4.5) <.001 51 (2) 36 (5.7) <.001
Hospital LOS, days 1.9 6 8 3 6 5.2 <.001 1.7 6 3 3 6 6.4 <.001
One-year outcomes
Death 64 (2.6) 23 (3.7) .128 82 (3.3) 35 (5.6) .006
Stroke 50 (2) 19 (3.1) .113 66 (2.6) 23 (3.7) .162
Stroke or death 114 (4.6) 39 (6.3) .082 145 (5.8) 54 (8.6) .009
CHF, Congestive heart failure; LOS, length of stay; MI, myocardial infarction.
Continuous data are presented as mean ± standard deviation and categoric data as number (%).
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